Patient Characteristics at Baseline
| Biomarker | |||||||
|---|---|---|---|---|---|---|---|
| Patient | Age (y) | Time since diagnosis (y) | ECOG | PSA | ALP | Prior treatment for prostate cancer | Comorbidity |
| ID01 | 81 | 18 | 1 | 0.75 | 64 | RALP, SP, HTx, BT, ARPI, EBRTp | AF, HT, HC, SN, AP, OP, HH |
| ID02 | 73 | 8 | 1 | 0.44 | 134 | HTx, EBRTx, CTx, EBRTp, ARPI | CP, AMD |
| ID03 | 89 | 14 | 1 | 15 | 101 | HTx, EBRTx, BT, ARPI | HT |
ECOG = Eastern Cooperative Oncology Group score of performance status; PSA = prostate-specific antigen; ALP = alkaline phosphatase; RALP = robot-assisted laparoscopic prostatectomy; SP = sphincter prosthesis; HTx = antihormonal therapy; BT = bisphosphonate therapy; ARPI = androgen-receptor-pathway inhibitor; EBRTp = palliative local external-beam radiation therapy; AF = atrial fibrillation; HT = hypertension; HC = hypercholesterolemia; SN = sensory neuropathy; AP = sleep apnea; OP = osteoporosis with skeletal fractures; HH = hiatus hernia with esophagitis; EBRTx = external-beam radiation therapy for localized prostate cancer; CTx = chemotherapy; CP = columna prolapse; AMD = age-related macular degeneration.